Ascendis Pharma

Ascendis Pharma is a global biopharmaceutical company founded in 2007 and headquartered in Copenhagen, Denmark. It is publicly traded on Nasdaq under the ticker ASND. The company develops therapies using its proprietary TransCon prodrug technology platform, designed to produce treatments with best-in-class potential in terms of safety, efficacy, tolerability and convenience.

The firm's work spans endocrinology rare disease therapeutics, oncology and broader biopharmaceutical research and development. Its single named platform technology, TransCon, is described as a drug development platform rather than a single product. Ascendis Pharma also collaborates with companies worldwide through partner arrangements.

Ascendis Pharma operates research facilities in Germany and maintains offices in Europe and the United States, alongside its Copenhagen headquarters. The company states its core values as Patients, Science and Passion, with a mission-driven focus on making a meaningful difference in patients' lives and an emphasis on innovation and collaborative partnering.